Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305679 | 0.79 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1 | |
| SCHEMBL14104732 | 0.76 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL17139836 | 0.76 | HSP90AB1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL14104728 | 0.75 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL1304392 | 0.74 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL1304249 | 0.73 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1 | |
| SCHEMBL1304830 | 0.73 | HSP90AB1 (0.72) | HSP90AA1HSP90AB1 | |
| SCHEMBL12047148 | 0.72 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1 | |
| SCHEMBL14184189 | 0.71 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL22541233 | 0.71 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.